ProShares Trust has taken a significant step by requesting the withdrawal of its registration for the ProShares Ultra Roche fund. This decision, filed with the U.S. Securities and Exchange Commission (SEC) on October 19, 2026, reflects a strategic pivot for the investment firm.
The withdrawal request, made under Rule 477 of the Securities Act of 1933, indicates that ProShares has chosen not to proceed with the registration of the fund. Notably, no securities have been sold in connection with this registration, suggesting that the firm is reassessing its product lineup in a competitive market.
Background
ProShares Trust, identified by its Central Index Key (CIK) number 0001174610, is an investment firm incorporated in Delaware. The company operates in the investment industry, focusing on exchange-traded funds (ETFs). Recent filings show that the firm has been active, with multiple submissions, including a series of Post-Effective Amendments to its Registration Statement.
What the Filing Says
The SEC filing states, "the Trust, on behalf of its series ProShares Ultra Roche, respectfully requests that... the U.S. Securities and Exchange Commission consent to the withdrawal of Post-Effective Amendment 479 to the Trust's Registration Statement." This amendment was initially filed on June 3, 2026, and the withdrawal request is effective as of the filing date.
Impact
This withdrawal may affect potential investors who were considering the ProShares Ultra Roche fund, as well as the broader ETF market. Competitors in the investment space may see this as an opportunity to attract investors looking for similar products.
What's Next
The filing does not say what happens next regarding the ProShares Ultra Roche fund or any future plans for ProShares Trust.